Business Wire

NY-HCL-TECHNOLOGIES

Share
HCL Technologies Launches a Global Hackathon to Identify Long-Term Technology Solutions to the COVID-19 Pandemic

HCL Technologies , (HCL), a leading global technology company, today announced a multi-phase hackathon, “Better Health Hackathon: #CodeforCOVID19 ,” to crowdsource technology innovation to find solutions for the immediate and long-term societal impact of the COVID-19 pandemic, including pandemic containment and prevention; diagnosis, treatment and therapeutic management; recovery and return to normal; and systemic solutions for future crises.

As part of the program, HCL has partnered with Microsoft and International SOS , the world's largest medical and travel security services firm, who are providing business and technical oversight to the contest and feedback to team entries. In addition, the Better Health Hackathon is bringing together a wide-ranging and prestigious group of executives and companies, across multiple industries, to serve as judges and advisory panel members. This includes scholars from Johns Hopkins University, University of Cambridge, Tuck School of Business, The University of Queensland, Indian Institute of Technology, Kanpur, and subject matter experts from HCL.

The competition is open to technology innovators, entrepreneurs and problem solvers from the global developer community. To date the Better Health Hackathon has received more than 7500 registrations from 600+ unique organizations and academic institutions spanning 350 locations across 52 countries. To engage top talent in the coding community, the Hackathon is partnering with BeMyApp to leverage their expansive network of coders and tech enthusiasts. The Hackathon is open to eligible participants who are at least 18 years of age.

“The unique capabilities and strength of HCL’s global ecosystem of partners, coupled with the immense talent and best minds from the tech, developer and entrepreneur communities, enables us to make a significant contribution during the COVID-19 pandemic,” said Arthur Filip, Executive Vice President, Sales Transformation & Marketing, HCL Technologies. “Technology has a big role to play in alleviating the challenges brought on by the pandemic, addressing solutions for successful containment and the reorientation of business and society. We are honored to curate a very enthusiastic, committed and deeply talented global community to help us in this important work.”

Neeraj Balani, Managing Director, International SOS, India, said, “We are honored to be part of this initiative with our customer, HCL Technologies, and are confident that the outcomes will provide breakthroughs and benefits for employee health and wellness, which ultimately has a large impact on empowering business resilience, continuity and sustainability.”

Takuya Hirano, VP, Partner Services, Microsoft Corp., said, “This hackathon presents an opportunity for technology experts and innovative thinkers to showcase how advanced technology can help identify solutions to challenging problems facing societies. Technology can serve as a vehicle to drive new solutions that help improve the wellbeing of our communities and prepare us for future health challenges.”

Specifically, the HCL Better Health Hackathon: #CodeforCOVID19 will address the following areas:

  • Prevention and containment: #StayAtHome
    • This track explores solutions that better safeguard the most vulnerable in our communities, better communicate credible information, and help people better cope with the challenges of self-isolation. This track will examine: How can technology aid efforts to #FlattenTheCurve by offering a better quality of life to encourage people to #StayAtHome.
  • Diagnosis, treatment & therapeutic management
    • This track focuses on ways to help better protect and equip frontline healthcare workers and first responders, and to better serve those individuals and organizations seeking treatments and cures for COVID-19 with technology solutions.
  • Recovery and return to normal
    • This track dives into the next phase of society after shutdown orders are removed. In the absence of a tested and available vaccine or therapeutic treatments against COVID-19, how can technology safeguard communities against a relapse of an outbreak, once social distancing and other restrictions are lifted throughout the world, allowing people to return to public spaces.
  • Systemic solutions for crises and pandemic management
    • This track ideates innovative uses for next-gen technologies to plan for the long-term implications of COVID-19 and better prepare for future global pandemic-related challenges across healthcare and public services ecosystems.

About HCL Technologies

HCL Technologies (HCL) empowers global enterprises with technology for the next decade today. HCL’s Mode 1-2-3 strategy through its deep-domain industry expertise, customer-centricity and entrepreneurial culture of ideapreneurship™ enables businesses transform into next-gen enterprises.

HCL offers its services and products through three business units - IT and Business Services (ITBS), Engineering and R&D Services (ERS) and Products & Platforms (P&P). ITBS enables global enterprises to transform their businesses through offerings in areas of Applications, Infrastructure, Digital Process Operations and next generational digital transformation solutions. ERS offers engineering services and solutions in all aspects of product development and platform engineering while under P&P, HCL provides modernized software products to global clients for their technology and industry specific requirements. Through its cutting-edge co-innovation labs, global delivery capabilities and broad global network, HCL delivers holistic services in various industry verticals, categorized under Financial Services, Manufacturing, Technology & Services, Telecom & Media, Retail & CPG, Life Sciences & Healthcare and Public Services.

As a leading global technology company, HCL takes pride in its diversity, social responsibility, sustainability and education initiatives. As of 12 months ended June 30, 2020, HCL has a consolidated revenue of US $ 9.93 billion and its 150,287 ideapreneurs operate out of 49 countries.

Link:

ClickThru

Social Media:

https://www.facebook.com/HCLTechnologies/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye